Antiretroviral-associated hepatotoxicity

Current Infectious Disease Reports

Volumn 7, Issue 2, 2005, Pages 103-107

  Kress, Kendra D ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; DNA POLYMERASE; EFAVIRENZ; FLUCONAZOLE; INDINAVIR; LAMIVUDINE; LEUKOCYTE ANTIGEN; LIVER ENZYME; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THIAMINE; UNINDEXED DRUG;

DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; EOSINOPHILIA; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; MORBIDITY; MORTALITY; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; SUBSTANCE ABUSE; VIRUS HEPATITIS;

EID: 17044375500     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0068-z     Document Type: Review

References (34)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Puoti M, Torti C, Ripamonti D, et al.: HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003, 32:259-267.
3. Ogedegbe AO, Sulkowski MS: Antiretroviral-associated liver injury. Clin Liver Dis 2003, 7:475-499.
4. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32: 92-497.
5. Dieterich D: Managing antiretroviral-associated liver disease. J Acquir Immune Defic Syndr 2003, 34(Suppl 1): 34-S39.
6. Pol S, Lebray P, Vallet-Pichard A: HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004. 38(Suppl 2):S65-S72.
7. Nierenberg DW: "Did this drug cause my patient's hepatitis?" and related-questions. Ann Intern Med 2002, 136: 80-483.
8. Sabin CA: Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 2004, 38(Suppl 2): 56-S64.
9. Becker S: Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004, 38(Suppl 2):S49-S55.
10. Dieterich DT, Robinson PA, Love J, et al.: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004, 38(Suppl 2):S80-S89.
11. Kontorinis N, Dieterich DT: Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003, 23:173-182.
12. Manfredi R, Calza L, Chiodo F: Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004, 35:492-502.
13. Stern JO, Robinson PA, Love J, et al.: Nevirapine hepatic safety project. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, July 7-12, 2002.
14. Shepard K: Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter] Rigdefield, CT: Boehringer Ingelheim Pharmaceuticals; 2004.
15. Patel SM, Johnson S, Belknap SM: Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Aquir Immune Defic Syndr 2004, 35:120-125.
16. For the PACTG 1022 Study Team: Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG1022. J Acquir Immune Defic Syndr 2004, 36:772-776.
17. Gonzalez D, Jiménez-Nácher I, Romero M, et al.: Changes in nevirapine plasma concentrations along 48 weeks and relationship with transaminase elevations [abstract 856]. Antivir Ther 2003, (Suppl 1):S425.
18. Geel J, Pitt J, Orrell CJ, et al.: The effect of fluconazole on nevirapine pharmacokinetics [abstract WeOr1239]. Program and abstracts of the XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
19. Almond LM, Boffito M, Hoggard PG, et al.: The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004, 20: 16-722.
20. Dailly E, Billaud E, Reliquet V, et al.: No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004, 60:343-348.
21. Mallal S, Martin A, Cameron P, et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 *0101 abrogated by low CD4+ T cell counts. Program and abstracts of the XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
22. Sulkowski MS: Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004, 38(Suppl 2):S90-S97.
23. Sulkowski MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003, 23:183-194.
24. Sulkowski MS, Mehta SH, Chaisson RE, et al.: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18: 277-2284.
25. Montessori V, Harris M, Montaner JS: Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003, 23:167-172.
26. Montaner JS, Cote HC, Harris M, et al.: Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 2004, 38(Suppl 2):S73-S79.
27. Braitstein P, Palepu A, Dieterich D, et al.: Special considerations in the initation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 2004, 18:2221-2234.
28. Bonacini M: Liver injury during highly active antiretroviral therapy: the effect of hepatitis C co-infection. Clin Infect Dis 2004, 38(Suppl 2):S104-S108.
29. French AL, Benning L, Anastos K, et al.: Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis coinfection. Clin Infect Dis 2004, 39:402-410.
30. Uberti-Foppa C, De Bona A, Morsica G, et al.: Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33:146-152.
31. Macias J, Castellano V, Merchante N, et al.: Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004, 18:767-774.
32. Aranzabal L, Casado JL, Moya J, et al.: HAART-associated hepatotoxicity in HIV/HCV co-infected patients: the role of liver histologic damage and drug level [abstract PL14.1]. Program and abstracts from the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, November 14-18, 2004.
33. Soriano V, Massimo P, Sulkowski, et al.: Care of patients with hepatitis C and HIV co-infected. AIDS 2004, 18: -12.
34. Powderly WG: Antiretroviral therapy in patients with hepatitis and HIV: weighing risk and benefits. Clin Infect Dis 2004, 38(Suppl 2):S109-S113.